1Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial2020 · 198 citations
2CDC growth charts: United States.2000 · 5,175 citations
3Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia1994 · 1,332 citations

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial2020 · 198 citations
2CDC growth charts: United States.2000 · 5,175 citations
3Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia1994 · 1,332 citations

Sichere und anhaltende wachstumsfördernde Effekte von Vosoritid bei Kindern mit Achondroplasie: 2-Jahres-Ergebnisse aus einer offenen, Phase-3-Verlängerungsstudie | Synapse